Raily Aesthetic Medicine International Holdings Limited (HK:2135)
:2135
Want to see HK:2135 full AI Analyst Report?
2135 Stock Chart & Stats
HK$0.17
<HK$0.01(0.99%)
At close: 4:00 PM EST
HK$0.17
<HK$0.01(0.99%)
Day’s Range― - ―
52-Week RangeHK$0.11 - HK$0.20
Previous CloseN/A
Volume240.00K
Average Volume (3M)289.64K
Market Cap
HK$65.74M
Enterprise ValueHK$60.55M
Total Cash (Recent Filing)HK$57.82M
Total Debt (Recent Filing)HK$59.18M
Price to Earnings (P/E)33.0
Beta0.80
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding557,077,330
10 Day Avg. Volume121,000
30 Day Avg. Volume289,644
Financial Highlights & Ratios
PEG Ratio-0.41
Price to Book (P/B)0.70
Price to Sales (P/S)0.41
P/FCF Ratio2.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Return To Profitability (2025)The 2025 operational turnaround and return to small net profit signal that core operations can generate positive earnings after prior losses. Sustained margin recovery suggests management has addressed structural cost or pricing issues, improving the firm's ability to fund operations and rebuild reserves over the medium term.
Positive Free Cash Flow GenerationMaterial positive operating and free cash flow in 2025 provides durable financial flexibility: it reduces reliance on external financing, supports reinvestment in clinics and equipment, and enables working-capital stability. If cash generation remains consistent, it materially strengthens long-term solvency and strategic optionality.
Manageable LeverageA moderate debt-to-equity ratio around 0.55 indicates the balance sheet can absorb shocks without immediate refinancing stress. Stable leverage versus prior year supports capital allocation for growth or capex while preserving covenant headroom, helping the company sustain operations through demand cycles over the next several quarters.
Bears Say
Fragile Earnings QualityThin net margins and multiple prior years of losses imply earnings are sensitive to small revenue or cost shifts. That fragility means profit improvements may be reversible if patient volumes or pricing weaken, limiting visibility on durable profitability and making long-term earnings less reliable for reinvestment or distributions.
Volatile Cash Flows HistoricallyHistorical swings in operating cash flow, including past negative OCF, undermine confidence that 2025's positive free cash flow is sustainable. Volatile cash conversion can force reliance on external funding in down cycles, constrain capex, and increase refinancing risk, weakening long-term operational resilience.
Revenue Decline And Weak ReturnsNegative revenue growth and very low ROE indicate limited top-line momentum and poor capital efficiency. This combination suggests the business may struggle to scale profits from existing assets, pressuring future return generation and constraining the firm's ability to deliver durable shareholder value absent structural revenue improvement.
Raily Aesthetic Medicine International Holdings Limited News
2135 FAQ
What was Raily Aesthetic Medicine International Holdings Limited’s price range in the past 12 months?
Raily Aesthetic Medicine International Holdings Limited lowest stock price was HK$0.10 and its highest was HK$0.20 in the past 12 months.
What is Raily Aesthetic Medicine International Holdings Limited’s market cap?
Raily Aesthetic Medicine International Holdings Limited’s market cap is HK$65.74M.
When is Raily Aesthetic Medicine International Holdings Limited’s upcoming earnings report date?
Raily Aesthetic Medicine International Holdings Limited’s upcoming earnings report date is Aug 21, 2026 which is in 68 days.
How were Raily Aesthetic Medicine International Holdings Limited’s earnings last quarter?
Raily Aesthetic Medicine International Holdings Limited released its earnings results on Mar 27, 2026. The company reported HK$0.019 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.019.
Is Raily Aesthetic Medicine International Holdings Limited overvalued?
According to Wall Street analysts Raily Aesthetic Medicine International Holdings Limited’s price is currently Overvalued.
Does Raily Aesthetic Medicine International Holdings Limited pay dividends?
Raily Aesthetic Medicine International Holdings Limited does not currently pay dividends.
What is Raily Aesthetic Medicine International Holdings Limited’s EPS estimate?
Raily Aesthetic Medicine International Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Raily Aesthetic Medicine International Holdings Limited have?
Raily Aesthetic Medicine International Holdings Limited has 557,077,330 shares outstanding.
What happened to Raily Aesthetic Medicine International Holdings Limited’s price movement after its last earnings report?
Raily Aesthetic Medicine International Holdings Limited reported an EPS of HK$0.019 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Raily Aesthetic Medicine International Holdings Limited?
Currently, no hedge funds are holding shares in HK:2135
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Raily Aesthetic Medicine International Holdings Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-15.26%
12-Months-Change
Fundamentals
Return on Equity
1.67%
Trailing 12-Months
Asset Growth
-0.48%
Trailing 12-Months
Company Description
Raily Aesthetic Medicine International Holdings Limited
Raily Aesthetic Medicine International Holdings Limited is an investment holding company primarily engaged in providing a comprehensive range of cosmetic medical services. Its operations are structured into three principal segments: Aesthetic Medical Services, Consulting Services, and the distribution of Aesthetic Medical Equipment Products. The company's service offerings include various aesthetic procedures such as: Surgical interventions: encompassing cosmetic surgeries performed on different areas of the face or body. Minimally invasive treatments: largely consisting of aesthetic injection procedures. Aesthetic dermatology: featuring diverse energy-based treatments. Aesthetic dental care: including orthodontic services, dental implants, and teeth whitening. Management consulting: providing specialized advisory services for aesthetic medical practices. Furthermore, Raily trades in medical equipment and sells surgical implants alongside aesthetic medical skincare products. The company manages and operates a network of four private, for-profit aesthetic medical clinics located in China's Zhejiang and Anhui Provinces. It serves a diverse clientele, including individual retail customers and other aesthetic medical institutions. Founded in 2008 and headquartered in Hangzhou, People's Republic of China, Raily Aesthetic Medicine International Holdings Limited operates as a subsidiary of Ruide Consultation Limited.
Raily Aesthetic Medicine International Holdings Limited (2135) Earnings & Revenues
Technical Analysis
Beauty Farm Medical & Health Industry, Inc.
―
Town Health International Medical Group Ltd.
―
Arrail Group Ltd.
―
Medicskin Holdings Ltd.
―
Saint Bella Inc.
―